3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Sequence-based prediction of the intrinsic solubility of peptides containing non-natural amino acids

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Non-natural amino acids are increasingly used as building blocks in the development of peptide-based drugs as they expand the available chemical space to tailor function, half-life and other key properties. However, while the chemical space of modified amino acids (mAAs) such as residues containing post-translational modifications (PTMs) is potentially vast, experimental methods for measuring the developability properties of mAA-containing peptides are expensive and time consuming. To facilitate developability programs through computational methods, we present CamSol-PTM, a method that enables the fast and reliable sequence-based prediction of the intrinsic solubility of mAA-containing peptides in aqueous solution at room temperature. From a computational screening of 50,000 mAA-containing variants of three peptides, we selected five different small-size mAAs for a total number of 37 peptide variants for experimental validation. We demonstrate the accuracy of the predictions by comparing the calculated and experimental solubility values. Our results indicate that the computational screening of mAA-containing peptides can extend by over four orders of magnitude the ability to explore the solubility chemical space of peptides and confirm that our method can accurately assess the solubility of peptides containing mAAs. This method is available as a web server at https://www-cohsoftware.ch.cam.ac.uk/index.php/camsolptm.

          Abstract

          Posttranslationally modified amino acids are crucial in physiology and drug development as they alter physicochemical properties such as the solubility of proteins. Here the authors describe CamSolPTM, a software that accurately predicts the solubility of proteins containing these residues.

          Related collections

          Most cited references98

          • Record: found
          • Abstract: found
          • Article: not found

          Glycosylation in health and disease

          The glycome describes the complete repertoire of glycoconjugates composed of carbohydrate chains, or glycans, that are covalently linked to lipid or protein molecules. Glycoconjugates are formed through a process called glycosylation and can differ in their glycan sequences, the connections between them and their length. Glycoconjugate synthesis is a dynamic process that depends on the local milieu of enzymes, sugar precursors and organelle structures as well as the cell types involved and cellular signals. Studies of rare genetic disorders that affect glycosylation first highlighted the biological importance of the glycome, and technological advances have improved our understanding of its heterogeneity and complexity. Researchers can now routinely assess how the secreted and cell-surface glycomes reflect overall cellular status in health and disease. In fact, changes in glycosylation can modulate inflammatory responses, enable viral immune escape, promote cancer cell metastasis or regulate apoptosis; the composition of the glycome also affects kidney function in health and disease. New insights into the structure and function of the glycome can now be applied to therapy development and could improve our ability to fine-tune immunological responses and inflammation, optimize the performance of therapeutic antibodies and boost immune responses to cancer. These examples illustrate the potential of the emerging field of 'glycomedicine'.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Adding new chemistries to the genetic code.

            The development of new orthogonal aminoacyl-tRNA synthetase/tRNA pairs has led to the addition of approximately 70 unnatural amino acids (UAAs) to the genetic codes of Escherichia coli, yeast, and mammalian cells. These UAAs represent a wide range of structures and functions not found in the canonical 20 amino acids and thus provide new opportunities to generate proteins with enhanced or novel properties and probes of protein structure and function.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Post-translational modifications in the context of therapeutic proteins.

              The majority of protein-based biopharmaceuticals approved or in clinical trials bear some form of post-translational modification (PTM), which can profoundly affect protein properties relevant to their therapeutic application. Whereas glycosylation represents the most common modification, additional PTMs, including carboxylation, hydroxylation, sulfation and amidation, are characteristic of some products. The relationship between structure and function is understood for many PTMs but remains incomplete for others, particularly in the case of complex PTMs, such as glycosylation. A better understanding of such structural-functional relationships will facilitate the development of second-generation products displaying a PTM profile engineered to optimize therapeutic usefulness.
                Bookmark

                Author and article information

                Contributors
                ps589@cam.ac.uk
                mv245@cam.ac.uk
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                17 November 2023
                17 November 2023
                2023
                : 14
                : 7475
                Affiliations
                [1 ]Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, ( https://ror.org/013meh722) Cambridge, UK
                [2 ]GRID grid.417815.e, ISNI 0000 0004 5929 4381, Hit Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, ; Cambridge, UK
                [3 ]GRID grid.417815.e, ISNI 0000 0004 5929 4381, Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, ; Cambridge, United Kingdom
                [4 ]Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, ( https://ror.org/04wwrrg31) Gothenburg, Sweden
                [5 ]Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, ( https://ror.org/04wwrrg31) Gothenburg, Sweden
                [6 ]Present Address: Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, ( https://ror.org/04py35477) Martinsried, Germany
                Author information
                http://orcid.org/0000-0003-0597-5950
                http://orcid.org/0009-0003-4487-2628
                http://orcid.org/0000-0002-4106-8912
                http://orcid.org/0000-0003-4618-1583
                http://orcid.org/0009-0003-5085-1583
                http://orcid.org/0000-0003-0785-794X
                http://orcid.org/0000-0002-8061-4242
                http://orcid.org/0000-0002-6228-2221
                http://orcid.org/0000-0002-3616-1610
                Article
                42940
                10.1038/s41467-023-42940-w
                10656490
                37978172
                5920bb88-1dc9-4dfb-a9ac-2d26623cea09
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 6 March 2023
                : 26 October 2023
                Funding
                Funded by: UKRI 10061100 and 10059436
                Categories
                Article
                Custom metadata
                © Springer Nature Limited 2023

                Uncategorized
                computational biology and bioinformatics,drug discovery,peptides,software
                Uncategorized
                computational biology and bioinformatics, drug discovery, peptides, software

                Comments

                Comment on this article